BACKGROUND: The role of medication use in multiple myeloma (MM) risk remains unclear. METHODS: The Los Angeles County Multiple Myeloma Case-Control Study, comprising 278 MM cases and individually matched neighborhood controls, provided data to assess associations between medication use and MM risk. Odds ratios (OR) and 95 % confidence intervals (CI) were estimated using conditional logistic regression. RESULTS: Erythromycin (ever) use was associated with increased MM risk (OR 1.85, 95 % CI 1.13-3.03). This association was restricted to men (OR 3.77, 95 % CI 1.72-8.29) and was especially apparent among men who took two or more courses of erythromycin (OR 4.68, 95 % CI 1.70-12.87). CONCLUSIONS: Compared to females, males have lower levels of cytochrome P450 3A4 (CYP3A4), for which erythromycin is both a substrate and inhibitor. Use of CYP3A4-inhibiting drugs such as erythromycin in men may thus result in even lower levels of CYP3A4 and, consequently, higher levels of CYP3A4-metabolized substances. These results could potentially provide clues to explain discrepancies in MM incidence by sex. Consortial efforts to confirm these associations are warranted.
BACKGROUND: The role of medication use in multiple myeloma (MM) risk remains unclear. METHODS: The Los Angeles County Multiple Myeloma Case-Control Study, comprising 278 MM cases and individually matched neighborhood controls, provided data to assess associations between medication use and MM risk. Odds ratios (OR) and 95 % confidence intervals (CI) were estimated using conditional logistic regression. RESULTS:Erythromycin (ever) use was associated with increased MM risk (OR 1.85, 95 % CI 1.13-3.03). This association was restricted to men (OR 3.77, 95 % CI 1.72-8.29) and was especially apparent among men who took two or more courses of erythromycin (OR 4.68, 95 % CI 1.70-12.87). CONCLUSIONS: Compared to females, males have lower levels of cytochrome P450 3A4 (CYP3A4), for which erythromycin is both a substrate and inhibitor. Use of CYP3A4-inhibiting drugs such as erythromycin in men may thus result in even lower levels of CYP3A4 and, consequently, higher levels of CYP3A4-metabolized substances. These results could potentially provide clues to explain discrepancies in MM incidence by sex. Consortial efforts to confirm these associations are warranted.
Authors: Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar Journal: Blood Date: 2009-01-29 Impact factor: 22.113
Authors: Leah H Schinasi; Elizabeth E Brown; Nicola J Camp; Sophia S Wang; Jonathan N Hofmann; Brian C Chiu; Lucia Miligi; Laura E Beane Freeman; Silvia de Sanjose; Leslie Bernstein; Alain Monnereau; Jacqueline Clavel; Guido J Tricot; Djordje Atanackovic; Pierluigi Cocco; Laurent Orsi; James A Dosman; John R McLaughlin; Mark P Purdue; Wendy Cozen; John J Spinelli; Anneclaire J de Roos Journal: Br J Haematol Date: 2016-06-22 Impact factor: 6.998
Authors: Anneclaire J De Roos; John Spinelli; Elizabeth B Brown; Djordje Atanackovic; Dalsu Baris; Leslie Bernstein; Parveen Bhatti; Nicola J Camp; Brian C Chiu; Jacqueline Clavel; Wendy Cozen; Silvia De Sanjosé; James A Dosman; Jonathan N Hofmann; John R McLaughlin; Lucia Miligi; Alain Monnereau; Laurent Orsi; Mark P Purdue; Leah H Schinasi; Guido J Tricot; Sophia S Wang; Yawei Zhang; Brenda M Birmann; Pierluigi Cocco Journal: Occup Environ Med Date: 2018-08-18 Impact factor: 4.948